CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Proceeds from Long-Term Debt Issued
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Proceeds from Long-Term Debt Issued of $1.27 billion for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for the quarter ending 2026-06-27 was $352.80M, a 35.51% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for the quarter ending 2026-03-28 was $912.46M, a 119.16% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for the quarter ending 2025-12-27 was $156.67M, a 49.50% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for the quarter ending 2025-09-27 was $107.50M, a 54.37% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for fiscal 2025 was $1.23B, a 13.49% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for fiscal 2024 was $1.08B, a 39.32% increase from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for fiscal 2023 was $776.35M, a 73.70% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. proceeds from issuance of long-term debt for fiscal 2022 was $2.95B, a 57.53% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-27 | $352.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.27B 10-Q · filed 2026-08-05 | $1.42B derived: sum of 3 quarters · filed 2026-08-05 | $1.53B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $912.46M 10-Q · filed 2026-05-07 | $1.07B derived: sum of 2 quarters · filed 2026-05-07 | $1.18B derived: sum of 3 quarters · filed 2026-05-07 | $1.72B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $156.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $264.17M derived: sum of 2 quarters · filed 2026-02-18 | $811.19M derived: sum of 3 quarters · filed 2026-08-05 | $1.23B 10-K · filed 2026-02-18 |
| 2025-09-27 | $107.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $654.52M derived: sum of 2 quarters · filed 2026-08-05 | $1.07B 10-Q · filed 2025-11-05 | $1.18B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $547.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $963.36M 10-Q · filed 2026-08-05 | $1.07B derived: sum of 3 quarters · filed 2026-08-05 | $1.30B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $416.34M 10-Q · filed 2026-05-07 | $521.14M derived: sum of 2 quarters · filed 2026-05-07 | $756.72M derived: sum of 3 quarters · filed 2026-05-07 | $1.20B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $104.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $340.38M derived: sum of 2 quarters · filed 2026-02-18 | $780.70M derived: sum of 3 quarters · filed 2026-02-18 | $1.08B 10-K · filed 2026-02-18 |
| 2024-09-28 | $235.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $675.90M derived: sum of 2 quarters · filed 2025-11-05 | $976.78M 10-Q · filed 2025-11-05 | $1.42B derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $440.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $741.20M 10-Q · filed 2025-08-06 | $1.18B derived: sum of 3 quarters · filed 2026-02-18 | $1.24B derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $300.88M 10-Q · filed 2025-05-07 | $744.20M derived: sum of 2 quarters · filed 2026-02-18 | $795.44M derived: sum of 3 quarters · filed 2026-02-18 | $884.74M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $443.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $494.56M derived: sum of 2 quarters · filed 2026-02-18 | $583.85M derived: sum of 3 quarters · filed 2026-02-18 | $776.35M 10-K · filed 2026-02-18 |
| 2023-09-30 | $51.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $140.53M derived: sum of 2 quarters · filed 2024-11-06 | $333.03M 10-Q · filed 2024-11-06 | $486.80M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-07-01 | $89.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $281.80M 10-Q · filed 2024-08-07 | $435.56M derived: sum of 3 quarters · filed 2025-02-19 | $1.05B derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-04-01 | $192.50M 10-Q · filed 2024-05-09 | $346.26M derived: sum of 2 quarters · filed 2025-02-19 | $964.42M derived: sum of 3 quarters · filed 2025-02-19 | $2.18B derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $153.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $771.92M derived: sum of 2 quarters · filed 2025-02-19 | $1.99B derived: sum of 3 quarters · filed 2025-02-19 | $2.95B 10-K · filed 2025-02-19 |
| 2022-09-24 | $618.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.84B derived: sum of 2 quarters · filed 2023-11-08 | $2.80B 10-Q · filed 2023-11-08 | $3.63B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-25 | $1.22B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.18B 10-Q · filed 2023-08-09 | $3.01B derived: sum of 3 quarters · filed 2024-02-14 | $4.13B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-26 | $962.00M 10-Q · filed 2023-05-11 | $1.79B derived: sum of 2 quarters · filed 2024-02-14 | $2.91B derived: sum of 3 quarters · filed 2024-02-14 | $5.96B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-25 | $831.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $1.95B derived: sum of 2 quarters · filed 2024-02-14 | $5.00B derived: sum of 3 quarters · filed 2024-02-14 | $6.95B 10-K · filed 2024-02-14 |
| 2021-09-25 | $1.12B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $4.17B derived: sum of 2 quarters · filed 2022-11-02 | $6.12B 10-Q · filed 2022-11-02 | $6.94B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-26 | $3.05B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $5.00B 10-Q · filed 2022-08-03 | $5.82B derived: sum of 3 quarters · filed 2023-02-22 | $5.82B derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-27 | $1.95B 10-Q · filed 2022-05-04 | $2.77B derived: sum of 2 quarters · filed 2023-02-22 | $2.77B derived: sum of 3 quarters · filed 2023-02-22 | $2.78B derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-26 | $819.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $819.03M derived: sum of 2 quarters · filed 2023-02-22 | $821.20M derived: sum of 3 quarters · filed 2023-02-22 | $2.23B 10-K · filed 2023-02-22 |
| 2020-09-26 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $2.16M derived: sum of 2 quarters · filed 2021-11-03 | $1.41B 10-Q · filed 2021-11-03 | $2.70B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.41B 10-Q · filed 2021-08-04 | $2.70B derived: sum of 3 quarters · filed 2022-02-16 | $3.28B derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $1.41B 10-Q · filed 2021-05-04 | $2.70B derived: sum of 2 quarters · filed 2022-02-16 | $3.28B derived: sum of 3 quarters · filed 2022-02-16 | $4.48B derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | $1.29B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $1.87B derived: sum of 2 quarters · filed 2022-02-16 | $3.07B derived: sum of 3 quarters · filed 2022-02-16 | $3.36B 10-K · filed 2022-02-16 |
| 2019-09-28 | $585.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $1.78B derived: sum of 2 quarters · filed 2020-10-29 | $2.07B 10-Q · filed 2020-10-29 | $2.43B derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-29 | $1.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.49B 10-Q · filed 2020-08-05 | $1.85B derived: sum of 3 quarters · filed 2021-02-17 | $1.85B derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-30 | $290.11M 10-Q · filed 2020-05-07 | $652.94M derived: sum of 2 quarters · filed 2021-02-17 | $652.57M derived: sum of 3 quarters · filed 2021-02-17 | $1.96B derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-29 | $362.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $362.46M derived: sum of 2 quarters · filed 2021-02-17 | $1.67B derived: sum of 3 quarters · filed 2021-02-17 | $2.76B 10-K · filed 2021-02-17 |
| 2018-09-29 | -$367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.31B derived: sum of 2 quarters · filed 2019-11-06 | $2.39B 10-Q · filed 2019-11-06 | $2.40B derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-06-30 | $1.31B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $2.39B 10-Q · filed 2019-07-31 | $2.40B derived: sum of 3 quarters · filed 2020-02-11 | $2.49B derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-03-31 | $1.08B 10-Q · filed 2019-05-07 | $1.09B derived: sum of 2 quarters · filed 2020-02-11 | $1.18B derived: sum of 3 quarters · filed 2020-02-11 | $1.20B derived: sum of 4 quarters · filed 2020-02-11 |
| 2017-12-30 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | $100.63M derived: sum of 2 quarters · filed 2020-02-11 | $124.13M derived: sum of 3 quarters · filed 2020-02-11 | $236.86M 10-K · filed 2020-02-11 |
| 2017-09-30 | $93.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $116.53M derived: sum of 2 quarters · filed 2018-11-07 | $229.25M 10-Q · filed 2018-11-07 | $347.14M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-07-01 | $23.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $136.22M 10-Q · filed 2018-08-08 | $254.11M derived: sum of 3 quarters · filed 2019-02-13 | $298.92M derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-04-01 | $112.72M 10-Q · filed 2018-05-10 | $230.61M derived: sum of 2 quarters · filed 2019-02-13 | $275.42M derived: sum of 3 quarters · filed 2019-02-13 | $1.11B derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $117.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $162.69M derived: sum of 2 quarters · filed 2019-02-13 | $995.24M derived: sum of 3 quarters · filed 2019-02-13 | $1.04B 10-K · filed 2019-02-13 |
| 2016-09-24 | $44.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $877.36M derived: sum of 2 quarters · filed 2017-11-09 | $926.78M 10-Q · filed 2017-11-09 | |
| 2016-06-25 | $832.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $881.98M 10-Q · filed 2017-08-09 | ||
| 2016-03-26 | $49.42M 10-Q · filed 2017-05-10 | |||
| 2015-09-26 | $453.78M 10-Q · filed 2016-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |